Petmed Express (PETS) Stock Rating Lowered by ValuEngine

Petmed Express (NASDAQ:PETS) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

Several other brokerages also recently commented on PETS. BidaskClub upgraded shares of Petmed Express from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 9th. Northcoast Research set a $58.00 price target on shares of Petmed Express and gave the company a “buy” rating in a report on Wednesday, January 3rd. Finally, Noble Financial reiterated a “hold” rating on shares of Petmed Express in a report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $42.80.

Shares of Petmed Express (PETS) opened at $45.23 on Friday. Petmed Express has a fifty-two week low of $19.21 and a fifty-two week high of $57.80. The firm has a market cap of $931.79, a PE ratio of 25.13, a PEG ratio of 2.69 and a beta of 0.95.

Petmed Express (NASDAQ:PETS) last posted its earnings results on Monday, January 22nd. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.11. Petmed Express had a net margin of 12.84% and a return on equity of 34.04%. The firm had revenue of $60.10 million for the quarter, compared to the consensus estimate of $56.76 million. During the same period in the previous year, the firm posted $0.24 EPS. The business’s quarterly revenue was up 13.6% on a year-over-year basis. equities analysts forecast that Petmed Express will post 1.7 EPS for the current year.

In other Petmed Express news, Director Gian Fulgoni sold 20,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $44.38, for a total value of $887,600.00. Following the transaction, the director now directly owns 55,900 shares in the company, valued at approximately $2,480,842. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronald J. Korn sold 5,000 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $48.38, for a total transaction of $241,900.00. Following the completion of the transaction, the director now owns 68,833 shares in the company, valued at $3,330,140.54. The disclosure for this sale can be found here. Insiders have sold a total of 65,000 shares of company stock worth $3,229,500 over the last quarter. 4.00% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of the business. Cardinal Capital Management grew its stake in Petmed Express by 11.6% in the 3rd quarter. Cardinal Capital Management now owns 12,553 shares of the company’s stock worth $416,000 after acquiring an additional 1,309 shares in the last quarter. Sterling Investment Advisors Ltd. grew its stake in Petmed Express by 118.5% in the 4th quarter. Sterling Investment Advisors Ltd. now owns 2,950 shares of the company’s stock worth $134,000 after acquiring an additional 1,600 shares in the last quarter. New York State Common Retirement Fund grew its stake in Petmed Express by 8.2% in the 2nd quarter. New York State Common Retirement Fund now owns 22,400 shares of the company’s stock worth $909,000 after acquiring an additional 1,699 shares in the last quarter. Wells Fargo & Company MN grew its stake in Petmed Express by 1.4% in the 4th quarter. Wells Fargo & Company MN now owns 144,494 shares of the company’s stock worth $6,574,000 after acquiring an additional 2,039 shares in the last quarter. Finally, LS Investment Advisors LLC grew its stake in Petmed Express by 283.5% in the 4th quarter. LS Investment Advisors LLC now owns 2,861 shares of the company’s stock worth $130,000 after acquiring an additional 2,115 shares in the last quarter. Institutional investors and hedge funds own 92.01% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Petmed Express (PETS) Stock Rating Lowered by ValuEngine” was published by Week Herald and is owned by of Week Herald. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://weekherald.com/2018/02/23/petmed-express-pets-stock-rating-lowered-by-valuengine.html.

About Petmed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Analyst Recommendations for Petmed Express (NASDAQ:PETS)

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply